A
Amy Chadburn
Researcher at Cornell University
Publications - 206
Citations - 18491
Amy Chadburn is an academic researcher from Cornell University. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 189 publications receiving 16306 citations. Previous affiliations of Amy Chadburn include Hospital for Special Surgery & Northwestern University.
Papers
More filters
Journal ArticleDOI
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
David Lyden,Koichi Hattori,Koichi Hattori,Sergio Dias,Carla Costa,Pamela Blaikie,Linda J. Butros,Amy Chadburn,Beate Heissig,Willy Marks,Larry Witte,Yan Wu,Daniel J. Hicklin,Zhenping Zhu,Neil R. Hackett,Ronald G. Crystal,Malcolm A.S. Moore,Katherine A. Hajjar,Katia Manova,Robert Benezra,Shahin Rafii +20 more
TL;DR: It is demonstrated that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggested new clinical strategies to block tumor growth are suggested.
Journal ArticleDOI
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno,Wei Keat Lim,Adina Grunn,Subhadra V. Nandula,Manisha Brahmachary,Qiong Shen,Francesco Bertoni,Maurilio Ponzoni,Marta Scandurra,Andrea Califano,Govind Bhagat,Amy Chadburn,Riccardo Dalla-Favera,Laura Pasqualucci +13 more
TL;DR: The results demonstrate that NF-κB activation in DLBCL is caused by genetic lesions affecting multiple genes, the loss or activation of which may promote lymphomagenesis by leading to abnormally prolonged NF-σκB responses.
Journal ArticleDOI
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci,Vladimir Trifonov,Giulia Fabbri,Jing Ma,Davide Rossi,Annalisa Chiarenza,Victoria A. Wells,Adina Grunn,Monica Messina,Oliver Elliot,Joseph M. Chan,Govind Bhagat,Amy Chadburn,Gianluca Gaidano,Charles G. Mullighan,Raul Rabadan,Riccardo Dalla-Favera +16 more
TL;DR: By combining next-generation sequencing and copy number analysis, it is shown that the DLBCL coding genome contains, on average, more than 30 clonally represented gene alterations per case and novel dysregulated pathways underlying its pathogenesis are identified.
Journal ArticleDOI
CD133 expression is not restricted to stem cells, and both CD133 + and CD133 – metastatic colon cancer cells initiate tumors
Sergey V. Shmelkov,Jason M. Butler,Andrea T. Hooper,Adilia Hormigo,Jared S Kushner,Till Milde,Ryan St Clair,Muhamed Baljevic,Ian A. White,David K. Jin,Amy Chadburn,Andrew J. Murphy,David M. Valenzuela,Nicholas W. Gale,Gavin Thurston,George D. Yancopoulos,Michael I. D’Angelica,Nancy E. Kemeny,David Lyden,Shahin Rafii +19 more
TL;DR: The data suggest that CD133 expression is not restricted to intestinal stem or cancer-initiating cells, and during the metastatic transition, CD133+ tumor cells might give rise to the more aggressive CD133(- )subset, which is also capable of tumor initiation in NOD/SCID mice.
Journal ArticleDOI
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci,David Dominguez-Sola,Annalisa Chiarenza,Giulia Fabbri,Adina Grunn,Vladimir Trifonov,Lawryn H. Kasper,Stephanie Lerach,Hongyan Tang,Jing Ma,Davide Rossi,Amy Chadburn,Vundavalli V. Murty,Charles G. Mullighan,Gianluca Gaidano,Raul Rabadan,Paul K. Brindle,Riccardo Dalla-Favera +17 more
TL;DR: The results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin’s lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.